Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT) ...
Publication of annual report for financial year 2023Annual Shareholders™ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary...
Galapagos appoints Dickinson as Non-Executive independent Director to its Board
Galapagos halts lupus CAR-T work, confirms 100 layoffs this year
Full year 2023 key financials: Group net revenues of ‚¬783.5 million, including Jyseleca® net sales of ‚¬112.3 million Cash and current financial investments of ‚¬3.7 billion on 31 December...
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies Mechelen, Belgium; 15 February 2024,...
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business...
Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos™ point-of-care CAR-T product candidate in the San Francisco areaAgreement follows previously announced...
Galapagos Collaborates With BridGene Biosciences To Develop Cancer Treatments
BridGene Biosciences Announces Strategic Collaboration with Galapagos